Zacks: Analysts Anticipate Prothena Corporation PLC (PRTA) to Post -$1.38 EPS
Brokerages predict that Prothena Corporation PLC (NASDAQ:PRTA) will announce earnings per share (EPS) of ($1.38) for the current quarter, Zacks reports. Five analysts have made estimates for Prothena Corporation PLC’s earnings, with estimates ranging from ($1.54) to ($1.21). Prothena Corporation PLC reported earnings per share of ($1.26) in the same quarter last year, which suggests a negative year-over-year growth rate of 9.5%. The firm is expected to announce its next earnings report on Tuesday, November 7th.
According to Zacks, analysts expect that Prothena Corporation PLC will report full year earnings of ($4.51) per share for the current fiscal year, with EPS estimates ranging from ($4.80) to ($3.94). For the next year, analysts anticipate that the business will post earnings of ($5.03) per share, with EPS estimates ranging from ($6.82) to ($4.15). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that cover Prothena Corporation PLC.
Prothena Corporation PLC (NASDAQ:PRTA) last posted its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.89) by $0.43. Prothena Corporation PLC had a negative return on equity of 33.20% and a negative net margin of 527.56%. The company had revenue of $26.81 million for the quarter, compared to analysts’ expectations of $16.08 million. During the same period in the previous year, the firm posted ($1.18) EPS. Prothena Corporation PLC’s revenue was up 7951.1% compared to the same quarter last year.
A number of research analysts have recently weighed in on PRTA shares. Deutsche Bank AG reissued a “buy” rating on shares of Prothena Corporation PLC in a research note on Sunday, October 1st. Royal Bank Of Canada reissued a “buy” rating on shares of Prothena Corporation PLC in a research note on Friday, September 29th. Evercore ISI initiated coverage on shares of Prothena Corporation PLC in a research note on Wednesday, August 16th. They set an “outperform” rating and a $83.00 price objective for the company. ValuEngine lowered shares of Prothena Corporation PLC from a “hold” rating to a “sell” rating in a research report on Friday, October 6th. Finally, Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $70.00 target price on shares of Prothena Corporation PLC in a research report on Thursday, July 6th. One equities research analyst has rated the stock with a sell rating and fourteen have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $78.58.
In other Prothena Corporation PLC news, Director Dennis J. Selkoe sold 3,500 shares of Prothena Corporation PLC stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $64.17, for a total value of $224,595.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Tara Nickerson sold 17,500 shares of Prothena Corporation PLC stock in a transaction on Monday, September 25th. The shares were sold at an average price of $63.60, for a total transaction of $1,113,000.00. Following the completion of the transaction, the insider now owns 19,500 shares in the company, valued at approximately $1,240,200. The disclosure for this sale can be found here. In the last quarter, insiders sold 29,424 shares of company stock worth $1,922,787. 3.10% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently made changes to their positions in the business. Bank of New York Mellon Corp lifted its holdings in shares of Prothena Corporation PLC by 7.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 185,462 shares of the biotechnology company’s stock valued at $10,037,000 after acquiring an additional 13,492 shares in the last quarter. Sphera Funds Management LTD. acquired a new position in shares of Prothena Corporation PLC during the 2nd quarter valued at $2,165,000. Victory Capital Management Inc. acquired a new position in shares of Prothena Corporation PLC during the 1st quarter valued at $588,000. Alliancebernstein L.P. lifted its holdings in shares of Prothena Corporation PLC by 6.8% during the 2nd quarter. Alliancebernstein L.P. now owns 895,759 shares of the biotechnology company’s stock valued at $48,478,000 after acquiring an additional 57,002 shares in the last quarter. Finally, BlackRock Inc. lifted its holdings in shares of Prothena Corporation PLC by 95,458.7% during the 1st quarter. BlackRock Inc. now owns 2,733,934 shares of the biotechnology company’s stock valued at $152,526,000 after acquiring an additional 2,731,073 shares in the last quarter.
ILLEGAL ACTIVITY WARNING: This story was first reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.watchlistnews.com/zacks-analysts-anticipate-prothena-corporation-plc-prta-to-post-1-38-eps/1650167.html.
Shares of Prothena Corporation PLC (PRTA) traded up 0.07% on Wednesday, hitting $57.95. The stock had a trading volume of 175,612 shares. The stock’s market cap is $2.22 billion. Prothena Corporation PLC has a one year low of $40.58 and a one year high of $70.00. The company’s 50 day moving average is $62.53 and its 200 day moving average is $57.85.
About Prothena Corporation PLC
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.